Epigenomics AG And Roche (RHHBY) Diagnostics Extend R&D Collaboration Agreement
10/19/2005 5:13:08 PM
Berlin, Germany and Seattle, WA, USA - September 30, 2005 lll Epigenomics AG (Frankfurt, Prime Standard: ECX), a molecular diagnostics company developing tests based on DNA methylation, today announced an extension to its existing agreement with Roche Diagnostics, a world leader in molecular diagnostics. The R&D part of the collaboration, which covers the development of five cancer diagnostic tests, has been extended for a minimum of 6 months, with the option to prolong and potentially expand for another 18 months. Financial terms were not disclosed.
comments powered by